Oscar Health's Q1 2026 Earnings Call Announcement Heightens Focus on Risk-Adjustment Volatility

What happened

Oscar Health announced its 2026 first quarter earnings conference call, setting a critical date for investors to assess the company's underwriting trajectory. This call is pivotal because the DeepValue report highlights that Oscar's investment thesis hinges on stabilizing risk-adjustment payables after repeated increases in 2025, driven by higher-than-expected market morbidity. The FY26 profitability bridge requires a 450 basis point improvement in medical loss ratio (MLR) to 82.4%-83.4%, but filings reveal ongoing volatility with upward revisions to risk-adjustment estimates. If the Q1 2026 results show another rise in risk-adjustment payable or MLR remains elevated, it would break the thesis, indicating persistent cost pressures despite management's guidance. Therefore, this announcement underscores the need for investors to scrutinize the call for early signals on whether Oscar can execute its aggressive reset or if underlying issues persist.

Implication

If the call reveals flat risk-adjustment payables and declining MLR, it could support the base case valuation of $14 by suggesting the FY26 earnings bridge is intact, potentially boosting investor confidence. Conversely, another increase in risk-adjustment payable would signal ongoing volatility, likely breaking the thesis and driving the stock toward the bear case of $9 as market morbidity concerns resurface. The call may also provide insights into enrollment stability post-subsidy expiration and regulatory scrutiny, which could impact future growth and compliance costs. Management's commentary on early 2026 utilization trends will be critical, as any deterioration could undermine pricing assumptions and necessitate guidance adjustments. Ultimately, this event consolidates investment risk around observable datapoints that will either reinforce or shatter the narrative of a 2026 profitability inflection.

Thesis delta

The investment thesis remains unchanged but highly contingent on Q1 2026 results, with a potential shift if risk-adjustment payables stabilize, upgrading conviction to medium, or if they rise again, downgrading it to low and warranting an exit. Investors should be prepared to re-evaluate based on the call's disclosures, as failure to show progress breaks the FY26 earnings bridge and exposes underlying volatility.